This activity is designed to meet the educational needs of multiple sclerosis specialists, general neurologists, advanced practice neurology professionals, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Multiple sclerosis (MS) management has been evolving at a staggering rate for the past two decades, with nearly a third of the 21 available disease modifying therapies (DMTs) receiving their FDA approvals in just the past few years. To assist practitioners in parsing out the rationale for and clinical utitity of these and other late-stage agents, Efficient surveyed five renowned MS specialists regarding their perspectives on these advances. These results formed the base material for a CME initiative in which those same experts led small groups of clinicians in an eight-week learning experience. The groups participated in a variety of activities including self-study, live discussions, group tasks, and assessments. This activity highlights the most important elements that emerged across the experience including key strategies from experts and insights into where participants are truly struggling that likely resonate with other clinicians.
Upon completion of this activity, participants should be better able to: